Guggenheim Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Guggenheim Capital’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-83,807	Closed	-$318K	–	1972
2020 Q1	$318K	Buy	+83,807	New	+$361K	﹤0.01%	1520
2017 Q4	–	Sell	-285,574	Closed	-$2.1M	–	2858
2017 Q3	$2.1M	Buy	285,574 +25,113	+10%	+$160K	﹤0.01%	1622
2017 Q2	$1.77M	Sell	260,461 -12,340	-5%	-$91.1K	﹤0.01%	1718
2017 Q1	$2.58M	Buy	+272,801	New	+$2.72M	0.01%	1469

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Guggenheim Capital's PGNX Position: Q2 2020 in Review

Guggenheim Capital sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 83,807 shares — an estimated $318K sold.

Guggenheim Capital first reported a position in PGNX in Q1 2017 and held it in 4 quarters. The position peaked at $2.58M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Guggenheim Capital reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Guggenheim Capital sold 83,807 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $318K.
Guggenheim Capital first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 4 quarters.
Guggenheim Capital's Progenics Pharmaceuticals Inc position peaked at $2.58M in Q1 2017.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Guggenheim Capital's 13F filing for Q2 2020, filed 14 Aug 2020.